Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Phase 1
72
about 2.8 years
8–17
1 site in TN
What this study is about
Researchers are testing if a daily medication called Methylphenidate can help children with sickle cell disease improve their attention, thinking skills, and schoolwork. The trial will also look at any side effects of the medication and how parents make decisions about whether or not to use it.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Extended-Release Methylphenidate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)
oral (Disintegrating Oral Tablet)
Secondary: Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue modules, Parent Report, Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease modules, Parent Report
Psychiatry / Mental Health